Bieszczad, B.; Garbicz, D.; Åšwitalska, M.; Dudek, M.K.; Warszycki, D.; Wietrzyk, J.; Grzesiuk, E.; Mieczkowski, A.
Improved HDAC Inhibition, Stronger Cytotoxic Effect and Higher Selectivity against Leukemias and Lymphomas of Novel, Tricyclic Vorinostat Analogues. Pharmaceuticals 2021, 14, 851.
https://doi.org/10.3390/ph14090851
AMA Style
Bieszczad B, Garbicz D, Åšwitalska M, Dudek MK, Warszycki D, Wietrzyk J, Grzesiuk E, Mieczkowski A.
Improved HDAC Inhibition, Stronger Cytotoxic Effect and Higher Selectivity against Leukemias and Lymphomas of Novel, Tricyclic Vorinostat Analogues. Pharmaceuticals. 2021; 14(9):851.
https://doi.org/10.3390/ph14090851
Chicago/Turabian Style
Bieszczad, Bartosz, Damian Garbicz, Marta Świtalska, Marta K. Dudek, Dawid Warszycki, Joanna Wietrzyk, Elżbieta Grzesiuk, and Adam Mieczkowski.
2021. "Improved HDAC Inhibition, Stronger Cytotoxic Effect and Higher Selectivity against Leukemias and Lymphomas of Novel, Tricyclic Vorinostat Analogues" Pharmaceuticals 14, no. 9: 851.
https://doi.org/10.3390/ph14090851
APA Style
Bieszczad, B., Garbicz, D., Åšwitalska, M., Dudek, M. K., Warszycki, D., Wietrzyk, J., Grzesiuk, E., & Mieczkowski, A.
(2021). Improved HDAC Inhibition, Stronger Cytotoxic Effect and Higher Selectivity against Leukemias and Lymphomas of Novel, Tricyclic Vorinostat Analogues. Pharmaceuticals, 14(9), 851.
https://doi.org/10.3390/ph14090851